Results 11 to 20 of about 539 (92)

Real-World Outcomes in Pre-Existing Neovascular Age-Related Macular Degeneration Subjects Undergoing Avacincaptad Therapy for Geographic Atrophy [PDF]

Clinical Ophthalmology
Ryan B Rush,1– 3 Westin Klein,1,3 Sloan W Rush,1,2 Robert M Reinauer4 1Department of Ophthalmology, Panhandle Eye Group, Amarillo, TX, USA; 2Department of Surgery, Texas Tech University Health Science Center, Amarillo, TX, USA; 3Department of ...
Rush RB, Klein W, Rush SW, Reinauer RM
doaj   +2 more sources

Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions [PDF]

Frontiers in Pharmacology
Small RNA or oligonucleotide therapeutics represent a unique modality outside the traditional treatment paradigm of small molecule and protein-based drugs that have historically only targeted a small fraction of the proteome.
Joseph M. Cronin, Ai-Ming Yu
doaj   +2 more sources

Anti-complement drugs for the treatment of geographic atrophy and the release of silicone oil [PDF]

International Journal of Retina and Vitreous
Intravitreal injections are a common procedure in ophthalmology, often using syringes coated with silicone to aid piston movement and needles coated with silicone oil to facilitate penetration of the sclera. Pegcetacoplan and avacincaptad pegol, recently
Gustavo Barreto Melo, Geoffrey Guy Emerson   +1 more
doaj   +2 more sources

Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial [PDF]

Eye, 2023
Arshad M Khanani, Sunil Patel
exaly   +2 more sources

Real-World Experience of Geographic Atrophy Treatment With Avacincaptad Pegol [PDF]

Journal of Vitreoretinal Diseases
Jeanette Du, Mohsin Ali, Brian Do
exaly   +2 more sources

C5 inhibitor avacincaptad pegol treatment for geographic atrophy: A comprehensive review [PDF]

Immunotherapy
Arshad M Khanani, Anat Loewenstein, Carl J Danzig   +2 more
exaly   +2 more sources

Complement Inhibition in Geographic Atrophy: Clinical Evidence for Pegcetacoplan and Avacincaptad Pegol [PDF]

Cureus
Orozco Loaiza G, Alfaro Guerra MJ, Murillo Sotela A, Villalobos Villalobos P.   +3 more
exaly   +2 more sources

The Role of Inflammation in Age-Related Macular Degeneration—Therapeutic Landscapes in Geographic Atrophy

Cells, 2023
Age-related macular degeneration (AMD) is the leading cause of vision loss and visual impairment in people over 50 years of age. In the current therapeutic landscape, intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapies have been ...
Grace A. Borchert, Hoda Shamsnajafabadi, Monica L. Hu, Samantha R. De Silva, Susan M. Downes, Robert E. MacLaren, Kanmin Xue, Jasmina Cehajic-Kapetanovic   +7 more
doaj   +1 more source

Piloting a forced-choice task to elicit treatment preferences in geographic atrophy

BMC Research Notes, 2023
Objective Geographic Atrophy (GA) is the advanced form of the non-neovascular (‘dry’) type of age-related macular degeneration (AMD) and responsible for one-quarter of legal blindness in the UK.
Jamie Enoch, Arevik Ghulakhszian, Mandeep Sekhon, David P. Crabb, Deanna J. Taylor, Christiana Dinah   +5 more
doaj   +1 more source

Treating patients with geographic atrophy: are we there yet?

International Journal of Retina and Vitreous, 2023
Geographic atrophy (GA) is a progressive degenerative disease that significantly contributes to visual impairment in individuals aged 50 years and older. The development of GA is influenced by various modifiable and non-modifiable risk factors, including
Bani Antonio-Aguirre, J. Fernando Arevalo   +1 more
doaj   +1 more source